AI-generated analysis. Always verify with the original filing.
Moderna, Inc. reported Q4 2025 revenue of $678 million and a GAAP net loss of $(826) million, or $(2.11) per share. The Company reiterated its 2026 financial framework targeting up to 10% revenue growth and provided updates on regulatory submissions and clinical pipeline milestones.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On February 13, 2026, Moderna, Inc. issued a press release announcing its financial results for the fourth quarte
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Press release issued by Moderna, Inc. dated February 13, 2026 104 Cover Page Inte
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $678.00 | GAAP |
| Net Product Sales | $645.00 | GAAP |
| Net Loss | $-826.00 | GAAP |
| Loss Per Share | $-2.11 | GAAP |
| Research and Development Expenses | $775.00 | GAAP |
| Selling, General and Administrative Expenses | $308.00 | GAAP |
| Cost of Sales | $452.00 | GAAP |
Revenue Growth
up to 10%
Research and Development Expenses
approximately
GAAP
Selling, General and Administrative Expenses
approximately
GAAP
Cost of Sales
approximately
GAAP
Capital Expenditures
$0.2 to $0.3 billion
Year-end Cash and Investments
$5.5 to $6.0 billion